Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT02454283 is registered in ClinicalTrials.gov with Laguna Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02454283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02454283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Lead sponsor
Laguna Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2015
Completion date
November 30, 2015
Enrollment
41 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation or flutter